Betamethasone Benzoate

Summary

Betamethasone Benzoate (CHEMBL1200376) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 496.6 Da · C29H33FO6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200376
Name	Betamethasone Benzoate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5282492
Molecular formula	C29H33FO6
Molecular weight	496.6
InChIKey	SOQJPQZCPBDOMF-YCUXZELOSA-N

SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)OC(=O)C5=CC=CC=C5)C)O)F)C

IUPAC name: [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] benzoate

Also known as: Betamethasone benzoate, Uticort, W 5975, W-5975, BETAMETHASONE BENZOATE

Patent coverage: 1,002 distinct patent families (3,498 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).